Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Beyond Air Inc XAIR

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

GlobeNewswire May 20, 2025

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

GlobeNewswire April 24, 2025

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

GlobeNewswire April 21, 2025

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

GlobeNewswire April 15, 2025

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit(TM) GO at Home

GlobeNewswire April 9, 2025

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

GlobeNewswire April 1, 2025

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

GlobeNewswire March 31, 2025

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

GlobeNewswire March 24, 2025

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

GlobeNewswire March 11, 2025

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GlobeNewswire March 6, 2025

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire February 10, 2025

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

GlobeNewswire February 5, 2025

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

GlobeNewswire January 27, 2025

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

GlobeNewswire January 24, 2025

Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

GlobeNewswire January 6, 2025

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

GlobeNewswire December 3, 2024

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

GlobeNewswire December 2, 2024

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

GlobeNewswire November 26, 2024

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire November 14, 2024

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 11, 2024